Details of the Anti-TB Contract
Sai Parenterals has secured a major purchase order from PILL CORP, based in Bulacan, Philippines, for the supply of anti-tuberculosis (TB) products. The contract is valued at USD 11 million, translating to approximately ₹104.50 crore. This long-term agreement is structured on an exclusivity basis for the Philippines market, starting June 1, 2026.
Spanning a ten-year term, the contract mandates that purchase orders will be released periodically throughout the period. This ensures a consistent production schedule and operational continuity for the company's manufacturing facilities over the coming decade.
Strategic Partnership and Market Reach
The contract was awarded by PILL CORP, a critical international partner for market entry into the Philippines. By securing an exclusive supply arrangement, Sai Parenterals positions itself as a primary provider in a region with a high clinical burden of tuberculosis. The Philippines pharmaceutical market is projected to reach USD 3.9 billion by 2033, driven by a 76% volume share for generic drugs.
This partnership leverages Sai Parenterals' specialized manufacturing capabilities to meet international demand in a high-growth Southeast Asian segment, reinforcing its strategy of moving toward multi-year distribution frameworks.
Business Impact and Revenue Pipeline
This ₹104.50 crore order significantly bolsters the company's long-term revenue pipeline, representing nearly 27% of its annual operating revenue of ₹381 crore. The ten-year commitment allows for optimized capacity planning at its Hyderabad-based facilities, which include dedicated injectable and solid oral dosage units. Furthermore, the exclusivity clause establishes a defensive moat in the Philippines market, insulating the firm from competitors in the specific therapeutic categories covered.
This agreement follows recent strategic expansions, including a TGA-approved facility and entry into regulated markets like Australia and New Zealand.
Company Background
Headquartered in Hyderabad, Sai Parenterals specializes in sterile injectables, large-volume parenterals, and diversified formulations. The company operates through two main verticals: branded generics and Contract Development and Manufacturing Organisation (CDMO) services. With six manufacturing units, it serves both domestic government agencies and regulated international markets.
Recently listed in April 2026, the firm has demonstrated robust financial momentum, including a 137.88% annual revenue growth and a 297.49% surge in quarterly net profit. This new contract aligns with its focus on science-driven, affordable innovation and global regulatory excellence.
